Patient Rating:

No Rating Available?

Rodney R. Miles, M.D., Ph.D.

Patient Rating:

No Rating Available?

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 581-5854 ARUP
Hematopathology
500 Chipeta Way
Salt Lake City, UT 84108

Specialties

Bio

Dr. Miles is a staff hematopathologist at ARUP and an assistant professor of pathology at the University of Utah School of Medicine. Dr. Miles received his MD and a PhD in cell biology from the University of Nebraska. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology.

Dr. Miles is a member of the American Society of Hematology, the Society for Hematopathology, and the United States and Canadian Academy of Pathology.

Board Certification and Academic Information

Academic Departments Pathology - Assistant Professor
Academic Divisions Clinical Pathology
Board Certification American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Profile

Research Interests

  • Burkitt Lymphoma
  • Non-Hodgkin Lymphoma
  • Lymphoma, Large-Cell, Diffuse

Board Certification and Academic Information

Academic Departments Pathology - Assistant Professor
Academic Divisions Clinical Pathology
Board Certification American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Office Locations

Academic Office Phone Number Academic Office Address
ARUP Laboratories
500 S Chipeta Way
Salt Lake City, UT 84108
Emma Eccles Jones Research Building
Pathology
15 North Medical Drive East
Salt Lake City, UT 84112
Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Dr. Miles' research interests include pediatric cancer, specifically the identification and characterization of genomic differences that are related to prognosis in pediatric leukemia and lymphoma. Dr. Miles is a Huntsman Cancer Institute investigator and a member of the Nuclear Control of Cell Growth and Differentiation Program.

Education

Education History

Type School Degree
Fellowship University of Michigan
Hematopathology
Fellow
Research Fellow University of Michigan
Hematopathology
Research Fellow
Chief Resident University of Utah School of Medicine
Pathology
Chief Resident
Residency University of Utah School of Medicine
Pathology
Resident
Professional Medical University of Nebraska Medical Center
Medicine
M.D.
Doctoral Training University of Nebraska Medical Center
Cell Biology
Ph.D.
Undergraduate Grinnell College
Chemistry
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Smock KJ, Agarwal AM, Lim MS, Tripp SR, Miles RR, Patel JL, Abromowitch M, Lones MA, Cairo MS, Perkins SL (2/27/2014). Expression of Notch1 and mTOR Pathway Proteins in Pediatric Lymphoblastic Lymphoma; A Children's Oncology Group Report. Journal of Hematopathology, 7(1), 9-14.
  2. Sangle NA, Miles RR, Kelley TW, Perkins SL (10/31/2013). Aberrant Expression of Multiple T Antigens: CD4, CD5, and CD8 on Diffuse Large B-cell Lymphoma. Appl Immunohistochem Mol Morphol.
  3. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F (01/14/2013). NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell, 23(1), 48-62.
  4. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Mschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD (07/24/2013). VPREB1 Deletions occur independent of lambda-light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia.
  5. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS (11/11/2012). The genetic landscape of mutations in Burkitt lymphoma. Nat Genet.
  6. Ridges S, Joshi D, Heaton WL, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude G, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Mschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones D, Trede NS (06/14/2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 119(24), 5621-5631.
  7. Leventaki V, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR (9/2012). p53 Pathway Analysis in Paediatric Burkitt Lymphoma Reveals Increased MDM4 Expression as the only p53 Pathway Abnormality Detected in a Subset of Cases. Br J Haematol, 158(6), 763-771.
  8. Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, Sanmann JN, Althof PA, Sanger WG, Barnette P, Perkins SL, Miles RR (2011). Genome Wide Copy Number Analysis of Paediatric Burkitt Lymphoma Using Formalin Fixed Tissues Reveals a Subset with Gain of Chromosome 13q and Corresponding miRNA Over Expression. Br J Haematol, 155(4), 477-486.
  9. Hussain S, Foreman O, Perkins SL, Witzig TE, Miles RR, van Deursen J, Galardy PJ (2010). The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia, 24(9), 1641-55.
  10. Miles RR, Mankey CC, Seiler CE 3rd, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS, Lim MS (2009). Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol, 40(12), 1731-7.
  11. Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL (2008). Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer, 51(3), 369-74.

Review

  1. Miles RR, Arnold S, Cairo MS (2012). Risk Factors and Treatment of Childhood and Adolescent Burkitt Lymphoma/Leukaemia. [Review]. British Journal of Haematology, 156(6), 730-743.

Case Report

  1. Ho AK, Teman CJ, Smith GP, Nightingale DR, Miles RR (2011). Composite Mantle Cell and Diffuse Large B-Cell Lymphoma: Report of Two Cases. Int J Surg Pathol, 19(5), 643-648.

Editorial

  1. Miles RR, Cairo MS (9/13/2012). A pediatric translational perspective on the entity "progressive transformation of germinal centers (PTGC). Pediatr Blood Cancer, 60(1), 3-4.

Clinical Trials

Video & News